Search
for

    Sort by

    Research

    360-390 / 1000+ results

      research Finasteride

      March 2012 in “Reactions Weekly”

      research Finasteride

      August 2011 in “Reactions Weekly”

      research Finasteride

      May 2011 in “Reactions Weekly”

      research Finasteride

      April 2011 in “Reactions Weekly”

      research Finasteride

      March 2011 in “Reactions Weekly”

      research Finasteride

      April 2010 in “Reactions Weekly”

      research Finasteride

      September 2009 in “Reactions Weekly”

      research Finasteride

      August 2009 in “Reactions Weekly”

      research Finasteride

      February 2009 in “Reactions Weekly”

      research Finasteride

      October 2008 in “Reactions Weekly”

      research Finasteride

      October 2008 in “Reactions Weekly”

      research Finasteride

      February 2008 in “Reactions Weekly”

      research Finasteride

      November 2007 in “Reactions Weekly”

      research Finasteride

      January 2004 in “Reactions Weekly”

      research Finasteride

      March 2003 in “Reactions Weekly”

      research Finasteride

      October 2002 in “Reactions Weekly”

      research Finasteride

      September 2002 in “Reactions Weekly”

      research Finasteride

      February 2023 in “Reactions Weekly”

      research Finasteride

      January 2023 in “Reactions Weekly”

      research Finasteride

      May 2022 in “Reactions Weekly”

      research Finasteride

      December 2021 in “Reactions Weekly”

      research Finasteride

      August 2011 in “Reactions Weekly”

      research Finasteride

      April 2015 in “Reactions Weekly”

      research Finasteride

      May 2013 in “Reactions Weekly”

      research Finasteride

      December 2012 in “Reactions Weekly”

      research Finasteride

      January 2009 in “Reactions Weekly”

      research Transposon control as a checkpoint for tissue regeneration

      14 citations , November 2022 in “Development”
      This review discusses how transposable element activation may hinder tissue regeneration and explores mechanisms to control this activity, reporting no new experimental results.

      research Sacituzumab Govitecan-Hziy (Trodelvy™)

      3 citations , April 2021 in “Oncology Times”
      This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.